1. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer.
- Author
-
Jacobs D, Torabi SJ, Park HS, Rahmati R, Young MR, Mehra S, and Judson BL
- Subjects
- Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell surgery, Cohort Studies, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Staging, Oropharyngeal Neoplasms drug therapy, Oropharyngeal Neoplasms surgery, Papillomavirus Infections, Retrospective Studies, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell radiotherapy, Oropharyngeal Neoplasms pathology, Oropharyngeal Neoplasms radiotherapy
- Abstract
Objective: In 2014, the Radiation Therapy Oncology Group 1221 trial was initiated to analyze whether surgery with risk-based radiation therapy or chemoradiation therapy was superior to chemoradiation therapy alone in patients with clinically staged T1-2N1-2bM0 HPV-negative oropharyngeal squamous cell carcinoma. However, the study was prematurely terminated. Given the lack of a randomized controlled trial, we retrospectively approached the same question using large national cancer databases., Study Design: Retrospective cohort study., Setting: The National Cancer Database and Surveillance, Epidemiology, and End Results (SEER) program from 2010 to 2016., Methods: We identified 3004 patients in the National Cancer Database and 670 patients in the SEER database. Statistical techniques included Kaplan-Meier survival analysis, binary and multinomial logistic regressions, Cox proportional hazard regressions, and inverse propensity score weighting., Results: On weighted multivariable Cox regression, patients recommended to receive frontline surgery had improved overall survival as compared with those recommended to receive chemoradiation therapy alone (hazard ratio [HR], 0.77; 95% CI, 0.68-0.86). On post hoc multivariable analysis based on therapy actually received, frontline surgery with adjuvant chemoradiation therapy was associated with improved overall survival (HR, 0.59; 95% CI, 0.50-0.71) as compared with chemoradiation therapy without surgery. Analysis of the SEER cohort revealed improved overall survival (HR, 0.69; 95% CI, 0.54-0.87) and head and neck cancer-specific survival (HR, 0.59; 95% CI, 0.41-0.84) in patients recommended to receive frontline surgery over chemoradiation therapy alone., Conclusion: Our findings support the use of surgery with risk-based addition of adjuvant therapy in patients with cT1-2N1-2bM0 HPV-negative oropharyngeal cancer.
- Published
- 2021
- Full Text
- View/download PDF